A recent study revealed that bevacizumab (Avastin) provides survival benefits in patients with colorectal cancer (CRC) for ...
Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...
ISELIN, N.J. - Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company with a current market capitalization of $50.3 million, announced the appointment of Faisal G. Sukhtian as Chairman ...
Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo improved response rates and duration in BRAF V600E-mutant metastatic ...
Dr. Jennifer Kissner, SVP Clinical Development, discusses the 12-week safety and efficacy results for NORSE EIGHT clinical trial Watch the “What This Means” segment here ISELIN, N.J., Feb. 04, 2025 ...
Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...
Outlook Therapeutics, Inc.’s OTLK share price has dipped by 10.19%, which has investors questioning if this is right time to ...
On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest gratitude ...
News Medical on MSN14d
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancerPatients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
15d
Pfizer Inc. (PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback